KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance

KRAS is a small GTPase that is among the most commonly mutated oncogenes in cancer. Here, we discuss KRAS biology, therapeutic avenues to target it, and mechanisms of resistance that tumors employ in response to KRAS inhibition. Several strategies are under investigation for inhibiting oncogenic KRA...

Full description

Bibliographic Details
Published in:Current Oncology
Main Authors: Leonard J. Ash, Ottavia Busia-Bourdain, Daniel Okpattah, Avrosina Kamel, Ariel Liberchuk, Andrew L. Wolfe
Format: Article
Language:English
Published: MDPI AG 2024-04-01
Subjects:
KRAS
cancer
immunotherapy
targeted therapy
resistance
oncogene
Online Access:https://www.mdpi.com/1718-7729/31/4/150

Internet

https://www.mdpi.com/1718-7729/31/4/150

Similar Items